Definitive radiotherapy and Single-Agent radiosensitizing Ifosfamide in Patients with localized, irresectable Soft Tissue Sarcoma: A retrospective analysis
By: Franziska Eckert , Christiane Matuschek , Arndt-Christian Mueller , Martin Weinmann , Joerg T Hartmann , Claus Belka and Wilfried Budach

Radiation Oncology 2010, 5:55 doi:10.1186/1748-717X-5-55
Published: 16 June 2010

Abstract (Provisional)

Background and Purpose

Standard therapy for soft-tissue sarcomas remains complete resection. For primary radiotherapy local control rates of 30-45% have been reported. We analyzed retrospectively 11 cases of radiochemotherapy with single-agent ifosfamide in patients with macroscopic soft-tissue sarcomas.

Patients and Methods

The patients were treated in irresectable high risk situations. Radiation therapy was performed with median 60 Gy. During the first and fifth week the concomitant chemotherapy with ifosfamide was added. Two patients received trimodal therapy with additional regional hyperthermia.

Results

The therapy was completed in 73% of the patients. Average local control time was 91 months, median disease-free-survival/overall-survival was 8/26 months. Five-year rates for local control/disease free survival/overall survival were 70%/34%/34%. The limited prognosis is mainly caused by systemic treatment failure.

Conclusions

The data strongly suggest a better outcome of radiochemotherapy in combination with ifosfamide compared to radiotherapy alone and radiotherapy in combination with other radiosensitizers.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production






* Albert Einstein College of Medicine has been
awarded Acceditation with Commendation by
the ACCME

Copyright 2025 InterMDnet | Privacy Policy | Disclaimer | System Requirements